Qingdao Baheal Pharmaceutical Co., Ltd. (SHE: 301015) announced that the outbound investment and related‑party transaction of its wholly‑owned subsidiary, Baheal Health, has been completed and closed. Under the transaction, Baheal Health exercised warrant rights to subscribe for 15,214,385 shares of Series E‑1 preferred shares of Zap Medical System, Ltd. at an exercise price of USD 0.723 per share, for a total investment of approximately USD 11 million – deepening Baheal’s exposure to the U.S. radiosurgery equipment market and the ZAP‑X Gyroscopic Radiosurgery platform.
Transaction Milestone
| Item | Detail |
|---|---|
| Investor | Baheal Health (wholly‑owned subsidiary of Qingdao Baheal Pharmaceutical, SHE: 301015) |
| Target Company | Zap Medical System, Ltd. (U.S.) |
| Transaction Type | Outbound investment / related‑party transaction – warrant exercise and preferred share subscription |
| Instrument | Series E‑1 preferred shares |
| Shares Subscribed | 15,214,385 shares |
| Exercise Price | USD 0.723 per share |
| Total Investment | ≈ USD 11 million |
| Closing Status | Exercise Notice signed; proceeds paid; share subscription certificate issued; transaction completed and closed |
Deal Timeline & Structure
- March 2025 – Warrant Issuance: Zap Medical System, Ltd. issued to Baheal Health a warrant for the subscription of Series E‑1 preferred shares, establishing the framework for the equity investment.
- September 2026 – Exercise Decision: Baheal Health elected to exercise the warrant rights, subscribing for 15,214,385 Series E‑1 preferred shares at USD 0.723 per share for approximately USD 11 million in total.
- As of 16 Oct 2026 – Closing Completed: Baheal Health had signed the Exercise Notice and paid the warrant exercise proceeds; Zap Medical had issued a share subscription certificate; and the transaction was formally completed and closed.
Company Profile – Zap Medical & the ZAP‑X Platform
- Business Focus: A U.S. company mainly engaged in radiosurgery equipment.
- Core Product: The ZAP‑X Gyroscopic Radiosurgery platform (“ZAP‑X”) – a dedicated radiosurgery system built on a gyroscopic delivery architecture.
- Clinical Application: ZAP‑X is primarily used for radiosurgical treatment of brain tumors, lesions and other conditions of the head and neck, a modality that delivers highly focused radiation to intracranial and head‑and‑neck targets without open surgery.
- Strategic Fit: The investment extends Baheal’s medical‑device footprint into advanced radiation oncology equipment, complementing its pharmaceutical core with a stake in a U.S.‑based radiosurgery innovator.
Market Impact & Outlook
- Cross‑Border Device Exposure: The closing gives Baheal shareholders indirect exposure to the global radiosurgery market, where dedicated brain‑focused platforms compete with established stereotactic radiosurgery systems.
- Related‑Party Transaction Governance: As an outbound investment constituting a related‑party transaction, the deal reflects Baheal’s use of structured, disclosure‑compliant channels for overseas capital deployment by its SHE: 301015‑listed platform.
- Portfolio Synergies: Investors will watch for potential commercial linkages between Baheal’s China healthcare network and Zap Medical’s ZAP‑X platform, including market development and clinical adoption of the system (no specific collaboration announced).
- Capital Commitment: At approximately USD 11 million, the subscription represents a staged, warrant‑based entry into Zap Medical’s Series E‑1 preferred equity – a structure that allowed Baheal Health to time its investment between March 2025 and September 2026.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Baheal Pharmaceutical’s outbound investment in Zap Medical, the commercial prospects of the ZAP‑X Gyroscopic Radiosurgery platform, and potential synergies between the parties. Actual results may differ materially due to risks including regulatory clearances, market adoption of radiosurgery equipment, clinical and commercial execution by Zap Medical, and foreign exchange and cross‑border investment conditions. The transaction described has closed; no further investment commitments were disclosed.-Fineline Info & Tech
